The information provided by New Blue Health is grounded in the following reference families. We believe in source transparency, allowing our patients and clinical partners to verify the data that informs our educational content.
Note: Full DOI and PMID links are available on the individual evidence pages for each molecule.
Metabolic Optimization (Semaglutide & Tirzepatide)
- FDA Prescribing Information: Wegovy® (semaglutide) and Zepbound® (tirzepatide) official clinical documentation.
- The STEP Trial Program: "Semaglutide Treatment Effect in People with obesity" - Landmark Phase III RCTs (JAMA, NEJM).
- The SURMOUNT Trial Program: "Tirzepatide once weekly for the treatment of obesity" - Phase III clinical outcomes (NEJM).
Cellular & Regenerative (GHK-Cu, NAD+, Glutathione)
- Pickart L, et al.: "The Human Tri-peptide GHK and Tissue Remodeling." Journal of Biomaterials Science.
- Covarrubias AJ, et al.: "NAD+ metabolism and its roles in cellular processes." Nature Reviews Molecular Cell Biology.
- Sinclair DA, et al.: "Therapeutic potential of NAD-boosting molecules." Translational Medicine of Aging.
Hormonal & Performance (Sermorelin, Tesamorelin, PT-141)
- FDA Prescribing Information: Egrifta SV® (tesamorelin) clinical safety and indications.
- FDA Prescribing Information: Vyleesi® (bremelanotide / PT-141) official documentation.
- Clinical Endocrinology: Studies on Growth Hormone Releasing Hormones (GHRH) and IGF-1 axis modulation.